Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Worldwide clinical experience with cefoperazone.

A U Gerber, W A Craig

    Drugs
    |January 1, 1981
    PubMed
    Summary
    This summary is machine-generated.

    Cefoperazone, administered twice daily, demonstrated high clinical efficacy across various infections, including respiratory, urinary, and gynecological. This antibiotic showed effectiveness against both susceptible and resistant bacteria, with a favorable safety profile.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target.

    Antimicrobial agents and chemotherapy·2014
    Same author

    In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.

    Antimicrobial agents and chemotherapy·2013
    Same author

    In vivo pharmacodynamics of new lipopeptide MX-2401.

    Antimicrobial agents and chemotherapy·2010
    Same author

    In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models.

    Antimicrobial agents and chemotherapy·2008
    Same author

    [Clinical thermometry--theory and critical approach].

    Therapeutische Umschau. Revue therapeutique·2006
    Same author

    Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target.

    Antimicrobial agents and chemotherapy·2006
    Same journal

    The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

    Drugs·2026
    Same journal

    Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

    Drugs·2026
    Same journal

    Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

    Drugs·2026
    Same journal

    Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

    Drugs·2026
    Same journal

    Relacorilant: First Approval.

    Drugs·2026
    Same journal

    Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

    Drugs·2026
    See all related articles

    Area of Science:

    • Infectious Diseases
    • Pharmacology
    • Clinical Microbiology

    Background:

    • Cefoperazone is a third-generation cephalosporin antibiotic.
    • Evaluating the safety and efficacy of cefoperazone is crucial for its clinical application.

    Purpose of the Study:

    • To assess the clinical efficacy and safety of cefoperazone in treating various bacterial infections.
    • To compare cefoperazone's performance against other antibiotics.

    Main Methods:

    • Conducted 13 clinical trials (4 comparative, 9 non-comparative) across multiple continents.
    • Evaluated 1046 patients with diverse infections.
    • Monitored clinical response rates and adverse reactions.

    Main Results:

    Related Experiment Videos

  • Achieved an overall satisfactory clinical response in 88% of evaluable patients.
  • Demonstrated high efficacy in lower respiratory tract (92%), gynecological (98%), and other infections.
  • Effective against both cephalosporin-susceptible and resistant bacteria, including Pseudomonas aeruginosa.
  • Adverse reactions occurred in 8% of patients, primarily gastrointestinal and dermatological.

    • Conclusions:

    • Twice-daily cefoperazone is effective and safe for a wide range of bacterial infections.
    • Cefoperazone offers a valuable therapeutic option, comparable or superior to other antibiotics.
    • Its broad-spectrum activity makes it suitable for treating infections caused by both Gram-positive and Gram-negative pathogens.